Citeline Podcasts

A Man On Fire Fueled By A Mission To Find A Drug For Every Disease. by Citeline

Find out more now about US FDA’s Orphan Drug Designation (ODD) program, which qualifies sponsors for incentives including tax credits, exemption from user fees, and more. Learn more about which orphan subsets could qualify for ODD, in your free podcast episode

최근 스위스 바젤에서 열린 바이오 유럽 스프링 행사를 취재한 Scrip Intelligence기사를 요약한 내용입니다.

https://scrip.pharmaintelligence.informa.com/SC148077/Pharma-Giants-Urge-Biotechs-To-Get-In-Touch-As-Early-As-Possible

Quick Listen: Scrip's Five Must-Know Things:

https://scrip.pharmaintelligence.informa.com/SC148150/Quick-Listen-Scrips-Five-MustKnow-Things

Pink Sheet reporters and editors discuss the FDA’s upcoming advisory committee meeting for the controversial ALS cell therapy NurOwn, a proposal to batch test all drugs coming into the US amid problems conducting foreign inspections, and the FDA’s return to in-person meetings with industry.

More On These Topics From The Pink Sheet:

https://pink.pharmaintelligence.informa.com/PS147942/BrainStorms-ALS-Treatment-NurOwn-Filed-Over-Protest-Will-Get-US-FDA-Panel-Review

https://pink.pharmaintelligence.informa.com/PS147972/Batch-Testing-Of-All-Imported-Drugs-Floated-At-House-Appropriations-Hearing

https://pink.pharmaintelligence.informa.com/PS147971/US-FDA-Holds-First-Hybrid-Meeting-With-Industry

DMHC analysts discuss presentations from the Advanced Therapies conference

Supporting links

Cell and Gene Therapy Podcast

https://www.biomedtracker.com/reportdetail.cfm?reportid=1683

Editing The Future Report

https://www.biomedtracker.com/reportdetail.cfm?reportid=1608

Peripheral T-Cell Lymphoma (PTCL) Market Spotlight

https://www.biomedtracker.com/reportdetail.cfm?reportid=1050

Gene, Cell, & RNA Therapy Landscape Q4 2022 Report

https://www.biomedtracker.com/reportdetail.cfm?reportid=1721

Other platforms

Apple Podcasts -   https://podcasts.apple.com/us/podcast/pharma-intelligence-podcasts/id923189836​

Google Podcasts - https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5zb3VuZGNsb3VkLmNvbS91c2Vycy9zb3VuZGNsb3VkOnVzZXJzOjEwNjU1NDkyOC9zb3VuZHMucnNz​

TuneIn - https://tunein.com/podcasts/Business--Economics-Podcasts/Pharma-Intelligence-Podcasts-p1140128/​

Spotify Podcasts - https://open.spotify.com/show/3DTc3eIh4xI6pVOd6DdO67​

In this special podcast from Medtech Insight, editor Reed Miller talked to Andrie Leday, the US vice president for ambulatory surgery centers (ASCs) at Johnson & Johnson/DePuy Synthes. Leday's group is dedicated to creating a new "ecosystem" around DePuy Synthes broad range of orthopedic implants and tools to meet the demand of an aging population.

Further Reading

For more information on DePuy Synthes and the growth of ambulatory surgery centers, check out these articles from Medtech Insight.

J&J Subsidiary Pays $9.75M To Resolve Kickback Allegations

AAOS 2022 Roundup: Stryker, Zimmer Biomet, J&J’s DePuy Synthes, Canary Medical

Future Of Surgery: Virtual Reality, Robotics And Collaboration

Minute Insight: Zimmer Biomet Adds Biointegrative Repair Products With Embody Acquisition

Exec Chat: OIC Expects To Disrupt Orthopedic Surgery Market With High Value Implants

Further Listening

Our other podcasts are available on Apple Podcasts, Google Podcasts, SoundCloud and TuneIn - also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider.

Quick Listen: Scrip's Five Must-Know Things

https://scrip.pharmaintelligence.informa.com/SC148112/Quick-Listen-Scrips-Five-MustKnow-Things

Pink Sheet reporter and editors discuss Moderna CEO’s Stéphane Bancel’s defense of his company and COVID-19 vaccine pricing at the Senate Health, Education, Labor and Pensions Committee, the NIH denying a petition to use government march-in rights for Xtandi, and Tofersen receiving a positive US FDA advisory committee recommendation for use in ALS.

More on these topics from The Pink Sheet:

Moderna CEO Hearing Highlights Dissatisfaction With Patient Assistance Programs

https://pink.pharmaintelligence.informa.com/PS147930/Moderna-CEO-Hearing-Highlights-Dissatisfaction-With-Patient-Assistance-Programs

Moderna CEO Reminds People About Value Of Government Negotiations At Senate Hearing

https://pink.pharmaintelligence.informa.com/PS147939/Moderna-CEO-Reminds-People-About-Value-Of-Government-Negotiations-At-Senate-Hearing

After Xtandi, Will Government Ever Seek March-In Rights Over Drug Pricing?

https://pink.pharmaintelligence.informa.com/PS147929/After-Xtandi-Will-Government-Ever-Seek-MarchIn-Rights-Over-Drug-Pricing

Xtandi Still Faces Likely US Price Cut Even As It Avoids ‘March In’ Proceeding

https://pink.pharmaintelligence.informa.com/PS147940/Xtandi-Still-Faces-Likely-US-Price-Cut-Even-As-It-Avoids-March-In-Proceeding

Accelerated Approval Is US FDA Panel’s Preferred Path For Biogen/Ionis’s Tofersen In ALS

https://pink.pharmaintelligence.informa.com/PS147918/Accelerated-Approval-Is-US-FDA-Panels-Preferred-Path-For-BiogenIoniss-Tofersen-In-ALS

Accelerated Approval: Potential Sources Of Confirmatory Evidence Weighed At Tofersen Review

https://pink.pharmaintelligence.informa.com/PS147937/Accelerated-Approval-Potential-Sources-Of-Confirmatory-Evidence-Weighed-At-Tofersen-Review

Medtech Insight sat down with Brittany Barreto, CEO of FemHealth Insights, who participated in a panel discussion at SXSW 2023 on the $1t femtech industry, to talk about her journey to becoming a women’s health care champion.